Latest News and Press Releases
Want to stay updated on the latest news?
-
Name Change Reflects Company’s Focus on Advancing Cannabinoid-Based Therapeutics as a Member of the Emerald Group Company to Trade on OTCQB Under Ticker EMBI at Market Open March 25, 2019 ...
-
Long Beach, CA, March 13, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to...
-
Prodrug of THC Improves Fluid Outflow Across Trabecular Meshwork and Positively Impacts Disease Markers Associated with Glaucoma-Related Fibrosis and Inflammation Changes in Neovascularization...
-
Enhanced Bioavailability Could Prove Pivotal in Providing Neuroprotection in Diseases of the Retina LONG BEACH, CA, March 04, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc....
-
LONG BEACH, CA, Oct. 15, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
-
Avtar Dhillon, MD, appointed as Executive Chairman of Nemus LONG BEACH, CA, Oct. 08, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE – Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the...
-
LONG BEACH, CA, Sept. 26, 2018 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE - NEMUS Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical...
-
Long Beach, CA, Aug. 01, 2018 (GLOBE NEWSWIRE) -- Nemus Bioscience, Inc. (OTCQB: NMUS), focused on the development of cannabinoid-based therapeutics to address global medical indications, especially...
-
Dr. David Schubert to advise Nemus on neuroprotection and CNS applications of the company’s proprietary cannabinoid portfolio COSTA MESA, CA. , March 21, 2018 (GLOBE NEWSWIRE) -- Nemus...
-
Nemus Bioscience Receives $400,000 Funding under Convertible Bridge Loan and Closes Initial $1,500,000 Private Placement COSTA MESA, Calif., Jan. 19, 2018 (GLOBE NEWSWIRE) -- NEMUS Bioscience, Inc....